Early detection of cancer
increases the chance of survival and/or curative treatment. While this is true
of all cancers, the World Health Organization puts emphasis on the value of
early diagnosis in cancers of the breast, cervix, mouth, larynx, colon, rectum
and skin. With particular focus on colorectal cancer, the third most common
cancer in the United States, tests are expensive (up to $10,000 per patient),
invasive and unpleasant, so most people don’t take advantage of them.
After the age of 50, healthcare
experts recommend a colonoscopy every five to ten years. Between these
colonoscopies, people can use non-invasive tests that can sometimes determine
the presence of cancer or even pre-cancers. The simple fact is that many people
choose not to get invasive yet potentially life-saving colonoscopies at all.
There are two main tests for
colorectal cancers in common clinical use, those which can detect cancer and
polyps (such as colonoscopy or flexible sigmoidoscopy), which are highly
invasive and expensive; and those that only detect cancer, such as the fecal
occult blood tests (FOBTs) and fecal immunochemical test (FIT).
FOBTs are used the most
frequently used test, most likely because they are available for less than $25,
and while a bit uncomfortable at the thought, are not physically invasive.
However, these tests have a high false positive rate and low rate of detecting
precancerous polyps. The FIT also detects blood in the stool, though it
achieves a higher detection rate (37 percent) than FOBT. The downsides to this
test are the approximately $100 cost and the fact that they may miss tumors
that bleed in small amounts or not at all.
VolitionRx is a life
sciences company focused on revolutionizing early detection, bringing to market
its inexpensive, accurate, and easy-to-use cancer detection blood tests. The
company’s current focus is on the detection of colorectal cancer, though future
plans call for expansion into detection of various other cancers as well.
The company’s NuQ suite of
products is based on proprietary Nucleosomics® technology, capable of measuring
and identifying nucleosome structures in the blood. Based on this technology,
VolitionRx is developing cancer screening tests and cancer diagnostic tests
that require a very small amount of blood, can be turned around in a day, and
are very cost effective. Following ongoing clinical trials and regulatory
approval, the company plans to offer its tests for individualized cancers under
the NuQ brand.
Human life is invaluable.
Sadly, the price and invasiveness associated with colorectal cancer have cost
many people their lives, resulting in a significant need for an improved
alternative for colorectal cancer diagnoses. VolitionRx’s blood-based approach
to cancer tests are designed to make detection simple and affordable,
revolutionizing cancer diagnosis.
For more information visit
www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
